| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(1 year, 8 months ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(6 years ago) | |
Nucynta is owned by Collegium Pharm Inc.
Nucynta contains Tapentadol Hydrochloride.
Nucynta has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Nucynta are:
- US6071970
- USRE39593
Nucynta was authorised for market use on 20 November, 2008.
Nucynta is available in tablet;oral, solution;oral dosage forms.
Nucynta can be used as relief of moderate to severe acute pain.
Drug patent challenges can be filed against Nucynta from 20 November, 2012.
The generics of Nucynta are possible to be released after 03 July, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 20 November, 2008
Treatment: Relief of moderate to severe acute pain
Dosage: TABLET;ORAL; SOLUTION;ORAL
NUCYNTA family patents
